KURA Insider Trading Activity and SEC Form 4 Filings
KURA insider trading summary
Over the past 12 months, insiders at Kura Oncology, Inc. (KURA) reported 40 sales worth $3.8M by 7 insiders and 2 open-market purchases worth $2.4M by 1 insider on SEC Form 4. Net insider selling was $1.5M.
Latest KURA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 29, 2026 | Brian T. Powl | Chief Commercial Officer | Sell | $166K (15,430 @ $10.75) |
| Sep 29, 2026 | Kathleen Ford | Chief Operating Officer | Sell | $39K (3,668 @ $10.75) |
| Sep 29, 2026 | Mollie Leoni | Chief Medical Officer | Sell | $310K (28,802 @ $10.75) |
| Sep 28, 2026 | Teresa Brophy Bair | Chief Legal Officer | Sell | $89K (8,442 @ $10.50) |
| Sep 28, 2026 | Mollie Leoni | Chief Medical Officer | Sell | $131K (12,448 @ $10.50) |
| Sep 28, 2026 | Brian T. Powl | Chief Commercial Officer | Sell | $84K (8,000 @ $10.56) |
| Sep 28, 2026 | Kathleen Ford | Chief Operating Officer | Sell | $72K (6,906 @ $10.50) |
| Sep 28, 2026 | Brian T. Powl | Chief Commercial Officer | Sell | $95K (9,020 @ $10.50) |
| Sep 28, 2026 | Thomas James Doyle | SVP, Finance & Accounting | Sell | $48K (4,607 @ $10.50) |
| Sep 24, 2026 | Francis Burrows | Chief Scientific Officer | Sell | $225K (20,726 @ $10.83) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.